14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
PMI vs RDN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Radian Group Inc. (RDN) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PMI carries a Unified Composite Score of 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin), whereas RDN carries 34.9/100 (SELL) at $36.47 (6.9x Forward P/E, 45.4% operating margin).
Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. RDN 34.9/100 SELL), RDN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (45.4% vs. -248.1% operating margin) and revenue trajectory (+105.7% vs. +38.6% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PMI vs RDN. Trailing 12-month operating profitability (PMI -248.1% vs RDN 45.4%) and valuation multiples (PMI N/M vs RDN 6.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $17.1M market capitalization and -248.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
RDN Moat ProfileHigh-Margin Pricing Power Moat
Insurance - Specialty Operator
Competes within the Insurance - Specialty value chain with $4.6B market capitalization and 45.4% operating margin.
OpEx & R&D Reinvestment17.1% of Rev ($337M)
90D Engineering Disclosures0 Published
Investor FAQ PMI vs RDN Key Questions & Quantitative Answers
As of Nov 19, 2026, Radian Group Inc. (RDN) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PMI carries a Unified Composite Score of 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin), whereas RDN carries 34.9/100 (SELL) at $36.47 (6.9x Forward P/E, 45.4% operating margin). Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. RDN 34.9/100 SELL), RDN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (45.4% vs. -248.1% operating margin) and revenue trajectory (+105.7% vs. +38.6% YoY).
RDN leads the Growth & Scale pillar: PMI posts +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin), compared with RDN at +105.7% YoY revenue growth and +18.4% YoY earnings growth on $1.97B TTM revenue (62.5% gross margin, 45.4% operating margin). On trailing 12-month operating scale, PMI generates $6.3M in USD-normalized revenue versus $1.97B for RDN. In operating R&D and SG&A reinvestment, PMI deploys N/A (0 90-day corporate R&D disclosures) versus 17.1% of Rev ($337M) (0 disclosures) for RDN.
RDN screens cheaper on headline valuation multiples. PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin), whereas RDN trades at 6.9x Forward P/E, 8.7x Trailing P/E, 0.76x PEG, and 2.3x EV/Revenue (48.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PMI (0.0% ROE) versus RDN (12.4% ROE) capital efficiency.
In options market volatility and institutional positioning, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk). By comparison, RDN carries 28.8% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.07β · 26% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.